The EQ-5D is the only identified questionnaire in this study that measures the quality of life in a cardinal index value and thus meets the requirements of cost-utility analyzes.
It has been purposefully developed to generate a cardinal index of health, therefore it has considerable potential for use in economic valuation [ 9].
To estimate the utility of changes in health status we shall use the EuroQoL, a generic measure of health purposefully developed to generate a cardinal index of health, thus giving it considerable potential for use in economic evaluation.
BMI: Body mass index; CI: Confidence interval; DG: Diabetic gastroparesis; GCSI: Gastroparesis cardinal symptom index; GER: Gastric emptying rate; HRT: Hormonal replacement therapy; m ± SD: mean ± standard deviation; NOS: Nitric oxide; OR: Odds ratio; T2DM: Type 2 diabetes mellitus.
To assess whether the gastroparesis cardinal symptom index (GCSI), or any individual symptom, is associated with delayed gastric emptying in children, and to assess understanding of symptoms associated with delayed gastric emptying.
All patients completed a demographic questionnaire and the Gastroparesis Cardinal Symptom Index (GCSI).
All patients completed a demographic and lifestyle questionnaire as well as the validated Hebrew translation of the Gastroparesis Cardinal Symptom Index (GCSI) [ 11].
The primary outcome measurement was gastroparesis Cardinal Symptom Index (GCSI) [ 11] or a similar scale [ 12] to score dyspeptic symptoms, and the secondary outcome measure was gastric emptying detected by scintigraphy or radio-opaque markers [ 13].
These tests were repeated after 8, 12, and 20 weeks, and the severity of symptoms of gastroparesis was also assessed using the Gastroparesis Cardinal Symptom Index (GCSI) questionnaire (10).
In its short form, the Gastroparesis Cardinal Symptom Index (GCSI), which is based on the first nine questions of Patient Assessment of Upper Gastrointestinal Disorder Severity Symptom Index, has proved to be a reliable and valid tool for measuring symptom severity in patients with gastroparesis and gastrointestinal dysfunction (14).
